Prof. Frank C. Sciurba, Director of the Emphysema/COPD Research Center at the University of Pittsburgh, has dedicated his career to advancing COPD care across devices, biologics, and unmet clinical needs. As new interventions — from bronchial rheoplasty to IL-33–targeting monoclonal antibodies — move closer to the clinic, how should physicians navigate an increasingly complex treatment landscape? Prof. Sciurba breaks down the latest data, highlights where the evidence still falls short, and identifies the patient subgroups that current therapies continue to leave behind.